Imbruvica has a wide patent portfolio with about 80 patents owned. Focusing on the last patent, it is expected that the generic version of Imbruvica can potentially be released after 03 September 2036.
Imbruvica is extensively used for the treatment of various forms of lymphoma and leukemia. Key treatments include relapsed or refractory small lymphocytic lymphoma; chronic lymphocytic leukemia; waldenstrom's macroglobulinemia; mantle cell lymphoma; marginal zone lymphoma; chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy. The active ingredient, ibrutinib, plays a crucial role in these treatments.
Imbruvica's patent details outline a broad range of patents with the earlier ones expiring around end of 2026 to the last ones in 2036. Notably, the last patent protects the pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor which expires on 03 September 2036. Consequently, the Imbruvica generic release could occur post this date. Below are the details of the patent: